Month: November 2018

Immune Regulation announces positive results from Phase 1 clinical trial of PIN201104

Immune Regulation announces positive results from Phase 1 clinical trial of IRL201104 • Confirmed clean safety profile • No serious or severe adverse effects • Primary endpoints of safety and pharmacokinetic data achieved Stevenage, UK, 26 November 2018 – Immune Regulation Ltd. (‘Immune Regulation’ or the ‘Company’, formerly known as Peptinnovate), a biopharmaceutical company developing… Read more »

Peptinnovate announces change of name to Immune Regulation, strengthening of the Board and successful fundraise

Peptinnovate announces change of name to Immune Regulation, strengthening of the Board and successful fundraise Peptinnovate Ltd (‘Peptinnovate’ or the ‘Company’, a biotechnology company developing novel immune modulators for immunological and inflammatory diseases, announces that it has changed its corporate name from Peptinnovate to Immune Regulation with immediate effect. The new website for Immune Regulation… Read more »

Menu